Results Preview: Amgen, the juggler
This article was originally published in Scrip
Big biotech Amgen follows Johnson & Johnson into the reporting box on Wednesday 23rd January. Like J&J which reported its annual results on 22 January, Amgen shares with Lance Armstrong an interest in ESAs. Unlike the cyclist, they still have a lot riding on EPOs, and for Amgen they represent more than a fifth of the revenue base. Nevertheless, the firm has a number of other fish to fry as it manages the slow decline of its Aranesp (darbepoetin alfa)/Epogen (epoetin alfa) business, and it was confident enough at the end of the fourth quarter to raise its full-year group revenue guidance from $16.9-17.2 billion to $17.2-17.3 billion.
You may also be interested in...
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.
Sanofi pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.